Pherecydes Pharma S.A.

The stock sits in a weak long-term regime, trading below its 200-day moving average of 2.2877. With no 52-week range available, the setup reads as a depressed biotech profile rather than a confirmed trend reversal.

Street coverage is thin and the published consensus is unavailable, but the average target sits at 5.8, implying meaningful upside from current levels. No recent rating changes or target revisions point to a stable, low-conviction view rather than a fresh catalyst wave.

Execution has been uneven, with only 1 beat in the last 6 reported quarters and several negative EPS prints. Shareholders should watch whether revenue contraction eases from the latest -36.1% year-over-year pace and whether losses narrow from the current run rate.

No notable insider buying or selling in recent quarters. With no reported transactions, there is no clear discretionary signal from management to frame the near-term setup.

Profitability remains deeply negative, with gross margin at -25.6%, operating margin at -212.03%, and net margin at -153.85%. Revenue fell 36.1% year over year, while the balance sheet shows 2.54 million of debt against 1.04 million of cash, leaving net debt of about 1.50 million.

As a small French biotech focused on phage-based antibacterial treatments, it competes on scientific differentiation rather than scale. Relative to profitable healthcare peers, the valuation case rests on pipeline optionality, not current earnings power.